Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kay H. Chow"'
Autor:
Suzanne F. Jones, Daphne L. Farrington, Maciej J. Zamek-Gliszczynski, Jennifer F. Cooksey, Kimberley Jackson, Jhanelle E. Gray, Adeline Yeo, Kay H. Chow, George R. Simon, Les H. Brail, Jeffrey R. Infante, Howard A. Burris
Publikováno v:
Investigational New Drugs. 33:1187-1196
Purpose LY2090314 (LY) is a glycogen synthase kinase 3 inhibitor with preclinical efficacy in xenograft models when combined with platinum regimens. A first-in-human phase 1 dose-escalation study evaluated the combination of LY with pemetrexed/carbop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52002e2eecbdaf949ffdd28a885cce93
https://doi.org/10.1007/s10637-015-0278-7
https://doi.org/10.1007/s10637-015-0278-7
Autor:
Denis J. McCann, Maciej J. Zamek-Gliszczynski, Shelby Anderson, Haitao Hu, Kenneth C. Cassidy, Kimberley Jackson, Trent L. Abraham, Nathan A Furr, Robert J. Barbuch, Kay H. Chow, Palaniappan Kulanthaivel, Jeffrey J. Alberts
Publikováno v:
Drug Metabolism and Disposition. 41:714-726
LY2090314 (3-[9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro[1,4]diazepino[6,7,1-hi]indol-7-yl]-4-imidazo[1,2-a]pyridin-3-yl-1H-pyrrole-2,5-dione) is an intravenous glycogen synthase kinase-3 inhibitor in oncology trials. Drug disposition was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e3d7c0352b0827cce9d8d21712dceb1
https://doi.org/10.1124/dmd.112.048488
https://doi.org/10.1124/dmd.112.048488